The recoveries surged to 15,35,743 with a record 54,859 more people recuperating in the past 24 hours, taking the recovery rate to 69.33 per cent. The case fatality rate has dropped to about 2 per cent, the govt said.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.
On a continuous upward trajectory, India's recovery rate has touched 78 per cent.
The number of active cases dropped to 14,01,609.
The active cases comprise 0.04 per cent of the total infections, while the national COVID-19 recovery rate was recorded at 98.75 per cent, the ministry said.
The death toll climbed to 5,25,199 with 31 new fatalities, the data updated at 8 am stated.
The active cases have reduced to 16,35,993 comprising 5.73 per cent of the total infections, while the national COVID-19 recovery rate has improved to 93.08 per cent.
A total of 94,612 people recovered from coronavirus in a span of 24 hours, taking the national recovery rate to 79.68 per cent, while 92,605 people tested positive for the disease during the period, taking the total COVID-19 cases to 54,00,619.
The draft bill allows euthanasia for patients who can take informed decisions; doctors to be protected from liability.
In Jaipur, the combination of lopinavir and ritonavir, both second-line HIV drugs, was administered was administered on an elderly Italian couple undergoing treatment for Covid-19 at the SMS Hospital.
In a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.
The Indian Council of Medical Research's national task force for COVID-19 has decided against including antiviral drug Molnupiravir in the clinical management protocol for COVID-19 as of now, official sources said on Tuesday.
